Dmitrij Hristodorov is Partner at Forbion and core member of the investment team working on new investments across funds and therapeutic areas.

Before joining Forbion, he held roles in R&D Ophthalmology and Business Development at Bayer Pharma. His current portfolio covers various stages, treatment modalities and disease areas. To date, he serves as a board member for Oxular, ARMGO Pharma, Complement Therapeutics, Seamless Therapeutics and as a board observer for VectorY.

He previously served as a board observer and R&D committee member of Gyroscope Therapeutics that was acquired for up to $1.5BN by Novartis in December 2021.